Notes
Notes - notes.io |
Diana Ernst, RPh
December 21, 2017
FDA: Boxed Warning About Asthma-Related Death Removed for LABA/ICS Combos
Long-acting beta agonists, when used with inhaled cortocosteroids, did not significantly increase the risk of asthma-related
Long-acting beta agonists, when used with inhaled cortocosteroids, did not significantly increase the risk of asthma-related
Based on a review of four clinical safety trials, the Food and Drug Administration (FDA) has concluded that medications that contain long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) do not significantly increase the risk of serious asthma-related adverse events.
Specifically, these recently completed trials, which were required by the FDA in 2011, demonstrated that compared to ICS alone, the use of LABA + ICS was not significantly associated with an increased risk of asthma-related hospitalizations, intubation, or asthma-related death. In addition, the studies also showed that the use of this combination was more effective in reducing asthma attacks compared to ICS alone.
RELATED ARTICLES
Fasenra Approved for Severe Eosinophilic Asthma
Symbicort Gains Expanded COPD Indication
Dupilumab Beneficial for Patients with Severe Steroid-Dependent Asthma
Given the results of these trials, the Boxed Warning regarding asthma-related death has been removed from the drug labeling for medications that contain both an ICS and LABA. Medications that include this combination include Advair Diskus (fluticasone and salmeterol; GlaxoSmithKline), Advair HFA (fluticasone and salmeterol; GlaxoSmithKline), Airduo Respiclick (fluticasone and salmeterol; Teva), Breo Ellipta (fluticasone and vilanterol; GlaxoSmithKline), Dulera (mometasone and formoterol; Merck), and Symbicort (budesonide and formoterol; AstraZeneca).
With regard to LABA monotherapy, the Boxed Warning will continue to state that use of LABA alone without an ICS to treat lung inflammation is associated with an increased risk of asthma-related death.
Clinicians are being advised to refer to the most recently approved drug labeling when making decisions on treatment. Data from these studies have been added to labeling in the Warnings and Precautions section.
For more information visit FDA.gov.
y to share with others. Click here ...
|
|
Notes.io is a web-based application for taking notes. You can take your notes and share with others people. If you like taking long notes, notes.io is designed for you. To date, over 8,000,000,000 notes created and continuing...
With notes.io;
- * You can take a note from anywhere and any device with internet connection.
- * You can share the notes in social platforms (YouTube, Facebook, Twitter, instagram etc.).
- * You can quickly share your contents without website, blog and e-mail.
- * You don't need to create any Account to share a note. As you wish you can use quick, easy and best shortened notes with sms, websites, e-mail, or messaging services (WhatsApp, iMessage, Telegram, Signal).
- * Notes.io has fabulous infrastructure design for a short link and allows you to share the note as an easy and understandable link.
Fast: Notes.io is built for speed and performance. You can take a notes quickly and browse your archive.
Easy: Notes.io doesn’t require installation. Just write and share note!
Short: Notes.io’s url just 8 character. You’ll get shorten link of your note when you want to share. (Ex: notes.io/q )
Free: Notes.io works for 12 years and has been free since the day it was started.
You immediately create your first note and start sharing with the ones you wish. If you want to contact us, you can use the following communication channels;
Email: [email protected]
Twitter: http://twitter.com/notesio
Instagram: http://instagram.com/notes.io
Facebook: http://facebook.com/notesio
Regards;
Notes.io Team
